Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy

• Published in: Aging (Albany, NY.) NY.), 2009-06, Vol.1 (6), p.515-528
• Main Authors: Armour, Sean M, Baur, Joseph A, Hsieh, Sherry N, Land-Bracha, Abigail, Thomas, Sheila M, Sinclair, David A
• Format: Article
• Language: English
• Subjects: Animals; Autophagy - drug effects; Autophagy - physiology; Cell Line; Humans; Mice; Priority Research Paper; Quercetin; Resveratrol; Ribosomal Protein S6 Kinases, 70-kDa - antagonists & inhibitors; Ribosomal Protein S6 Kinases, 70-kDa - metabolism; Sirolimus - pharmacology; Stilbenes - chemistry; Stilbenes - pharmacology
• ISSN: 1945-4589; 1945-4589
• DOI: 10.18632/aging.100056

Resveratrol is a plant-derived polyphenol that promotes health and disease resistance in rodent models, and extends lifespan in lower organisms. A major challenge is to understand the biological processes and molecular pathways by which resveratrol induces these beneficial effects. Autophagy is a critical process by which cells turn over damaged components and maintain bioenergetic requirements. Disruption of the normal balance between pro- and anti-autophagic signals is linked to cancer, liver disease, and neurodegenerative disorders. Here we show that resveratrol attenuates autophagy in response to nutrient limitation or rapamycin in multiple cell lines through a pathway independent of a known target, SIRT1. In a large-scalein vitro kinase screen we identified p70 S6 kinase (S6K1) as a target of resveratrol. Blocking S6K1 activity by expression of a dominant-negative mutant or RNA interference is sufficient to disrupt autophagy to a similar extent as resveratrol. Furthermore, co-administration of resveratrol with S6K1 knockdown does not produce an additive effect. These data indicate that S6K1 is important for the full induction of autophagy in mammals and raise the possibility that some of the beneficial effects of resveratrol are due to modulation of S6K1 activity.